Best Medications for Social Anxiety Disorder
SSRIs (selective serotonin reuptake inhibitors) are the first-line pharmacological treatment for social anxiety disorder in adults, with paroxetine, escitalopram, and sertraline showing the strongest evidence for efficacy. 1
Primary Medication Recommendations
First-Line: SSRIs
The 2023 Japanese guideline explicitly recommends SSRIs as the primary pharmacotherapy option 1. Among SSRIs, the evidence hierarchy is:
Paroxetine: Shows the most robust evidence, with superior efficacy in reducing symptom severity and achieving treatment response compared to placebo 2. A 2020 network meta-analysis identified paroxetine as having the strongest evidence base among all medications studied.
Escitalopram: Demonstrates consistent efficacy with good tolerability 1
Sertraline: Effective with evidence of treatment response 2, 3
Fluvoxamine: Effective but associated with higher dropout rates due to tolerability issues 2
Second-Line: SNRIs
Venlafaxine (extended-release) is the recommended SNRI, showing efficacy comparable to SSRIs 1, 4. However, it has higher withdrawal rates due to adverse events compared to SSRIs (RR 3.23 vs 2.59) 3.
Treatment Algorithm
Start with an SSRI (paroxetine, escitalopram, or sertraline) at standard dosing for anxiety disorders. These medications show:
- Risk ratio of 1.65 for treatment response vs placebo 3
- Moderate effect sizes (SMD -0.67) 4
- Evidence for relapse prevention (SSRIs are the only class demonstrating this) 3
If SSRIs fail or are not tolerated, switch to venlafaxine XR 1.
For performance-only social anxiety (limited to public speaking/performing), consider beta-blockers for situational use rather than daily SSRIs 5.
Alternative Medications (Lower Priority)
The following show efficacy but have significant limitations:
Benzodiazepines (clonazepam, bromazepam): High efficacy (RR 4.03) but carry abuse potential and should not be first-line 2, 3
MAOIs (phenelzine): Very effective (RR 2.36) but dietary restrictions and side effect profile limit use 2, 3
Anticonvulsants with GABA analogues (pregabalin): Moderate evidence (RR 1.60) but less robust than SSRIs 1
Critical Caveats
Tolerability considerations: While SSRIs have higher withdrawal rates than placebo (RR 2.59), the absolute withdrawal rates remain low 3. The evidence quality for SSRI efficacy ranges from very low to moderate, but this reflects the overall state of anxiety disorder research rather than lack of clinical effectiveness 3.
Time to response: Expect 6-12 weeks for full therapeutic effect. The guideline emphasizes that symptoms typically persist for 6+ months without treatment, so adequate trial duration is essential 1.
Avoid benzodiazepines as monotherapy despite their high efficacy due to dependence risk and lack of long-term data 3.
Combination with CBT: While the guideline found no definitive recommendation for combination therapy over monotherapy 1, individual CBT shows the largest effect sizes (SMD -1.19) and should be offered when available 6. When CBT is unavailable, SSRIs remain the appropriate first-line treatment 7, 4.